Precigen's commercial launch is doing what the early raise thesis needed it to do. Patient Capital Management calls $PGEN a "huge homerun" since leading the capital raise, and the tape backs it: $7.81

What happened: Patient Capital Management's Q3 2026 investor letter said Precigen (NASDAQ:PGEN) has been a 10-bagger since the firm led its capital raise in late 2024, driven by the launch of Papzimeous for recurrent respiratory papillomatosis. Key numbers: PGEN closed at $7.81 on October 09, 2026, market cap $2.8 billion, up about 86.84% YTD, 52-week range $3.04 to Why it matters: The firm said the stock price does not yet fully reflect Papzimeous value or other pipeline assets, citing FDA platform designation for Adenoverse and upcoming trial results in head-and-neck and cervical cancer. Market: -2.3% by next close ($7.48 on Oct 13), +71.8% YTD

Patient Capital Management's Q3 2026 investor letter said Precigen (NASDAQ:PGEN) has been a 10-bagger since the firm led its capital raise in late 2024, driven by the launch of Papzimeous for recurrent respiratory papillomatosis.

The firm said the stock price does not yet fully reflect Papzimeous value or other pipeline assets, citing FDA platform designation for Adenoverse and upcoming trial results in head-and-neck and cervical cancer. Market: -2.3% by next close ($7.48 on Oct 13), +71.8% YTD